Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family

Daekyu Sun, Galina Melman, Nickolas J. LeTourneau, Allison M. Hays, Artem Melman

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


We synthesized and evaluated new specific tridentate iron(III) chelators of 2,6-bis[hydroxyamino]-1,3,5-triazine (BHT) family for use in iron deprivation cancer therapy. Physical properties of BHT chelators are easily customizable allowing easy penetration through cellular membranes. Antiproliferative activity of new BHT chelators was studied on MDA-MB-231 and MiaPaCa cells and compared to a clinically available new oral iron chelator, deferasirox (DFX). The antiproliferative activity of new chelators was found to correlate with iron(III) chelation ability and some of analogs showed substantially higher antiproliferative activity than DFX.

Original languageEnglish (US)
Pages (from-to)458-460
Number of pages3
JournalBioorganic and Medicinal Chemistry Letters
Issue number2
StatePublished - Jan 15 2010


  • Antiproliferative
  • Cancer
  • Chelation
  • Cytotoxic
  • DFO
  • DFX
  • Hydroxamate
  • Hydroxylamine
  • Iron
  • Triazine

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family'. Together they form a unique fingerprint.

Cite this